MacuLogix Appoints Senior Vice President of Finance
Daniel Dorsey joins MacuLogix in key leadership role
HARRISBURG, PA, July 15, 2019 – MacuLogix®, Inc., the only company to equip eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), has appointed Daniel Dorsey as Senior Vice President of Finance. In this key role, Mr. Dorsey will oversee all aspects of financial operations and lead the overall fiscal strategy to further strengthen the company’s positioning and enhance value.
“Dan is an experienced leader with an impeccable track record for financial analysis, shareholder relations, risk management and staff development. His background spans across industries and brings a fresh perspective to our company,” said William McPhee, President and CEO of MacuLogix. “I look forward to joining forces to move our business forward and bring us closer to our mission of eliminating blindness caused by AMD.”
Mr. Dorsey has played critical roles in companies of varying sizes, and most recently excelled as a consultant for growing small public companies. Previously, he led finance, operations and strategic planning functions within a variety of media companies, including Rodale, Hudson News Distributors and Tribune Publishing Company. He holds a Bachelor of Science in Accounting from Indiana University of Pennsylvania and is a Certified Public Accountant.
“It’s great to join a company with a such a strong commitment to a shared vision of saving sight. I’m also impressed by the commercial opportunities that this one-of-a-kind technology provides. I look forward to leveraging my experiences to assist the company in achieving its financial objectives,” said Mr. Dorsey. “I am thrilled to be joining MacuLogix at such an exciting time as it expands its operations and continues to drive rapid adoption of its AdaptDx.”
After serving the company for nearly five years as Controller and Chief Financial Officer, Dennis Siegel has announced he will be retiring. In addition to naming Dan Dorsey as Senior Vice President of Finance, MacuLogix also hired Troy Lucas as its new Controller. Mr. Siegel will stay on through October to transition his responsibilities and finish overseeing the integration of an Enterprise Resource Planning system.
MacuLogix, Inc. equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx, MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Through its AdaptDx dark adaptation biomarker, MacuLogix enables eye care professionals to detect, monitor and treat AMD three years before it can be seen clinically. MacuLogix provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx.